Celgene Corporation prices USD1.5bn senior unsecured notes, with closing on 6 August 2013.
M2 EQUITYBITES-August 5, 2013-Celgene Corporation prices USD1.5bn senior unsecured notes, with closing on 6 August 2013(C)2013 M2 COMMUNICATIONS http://www.m2.com
Biopharmaceutical company Celgene Corporation (NasdaqGS:CELG) said on Friday that it has priced its USD1,500m senior unsecured notes in three series.
Of these notes, USD400m will mature in 2018 and will bear interest at an annual rate of 2.300%; USD700m will mature in 2023 and will bear interest at an annual rate of 4.000% and USD400m will mature in 2043 and will bear interest at an annual rate of 5.250%.
The company added the 2.300% notes due 2018, the 4.000% notes due 2023 and the 5.250% notes due in 2043 were priced to yield 2.344%, 4.067% and 5.307%, respectively.
Net proceeds are expected to be used by the company for general corporate purposes, the further development of its clinical and pre-clinical programmes, capital expenditures, general corporate development activities, meeting working capital needs, share repurchases of its common stock and repayment of some or all of its outstanding commercial paper.
This offering is expected to close on 6 August 2013. Barclays, Citigroup, Deutsche Bank Securities & JP Morgan are acting as joint book-running managers.
((Comments on this story may be sent to firstname.lastname@example.org)).END.PUB430>PDAugust 5, 2013>JNM2 EQUITYBITES.PRICEDATENOT APPLICABLE.DAY
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Aug 5, 2013|
|Previous Article:||TCI calls on EADS to offload Dassault stake - report.|
|Next Article:||Chemed Corporation's board reports 11.1% rise in quarterly dividend.|